The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.
Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.
The European Patent Office has issued a new CRISPR/Cas9 patent to inventor Emmanuelle Charpentier, one of the key figures in the CRISPR landscape.
Stanford University has accused genetic testing company Natera of infringing two patents that cover a non-invasive method of testing if transplanted organs are being rejected.
Biotech company Thermo Fisher Scientific has announced plans to acquire Brammer Bio, a viral vector manufacturer for gene and cell therapies, for $1.7 billion.
World Health Organization (WHO) experts have called for central registry on human genome editing research is needed, among a committee consensus that it would be irresponsible for any scientist to conduct gene-editing studies in people.
Press releases in recent months that suggest the CRISPR IP saga is about to end are too optimistic and miss out many of the nuances of the current situation, according to Claire Irvine, partner at HGF.
India’s government has cut the royalties its local seed companies and farmers pay to Monsanto by almost 50%.
The US Patent and Trademark Office has issued a third CRISPR patent to inventor Emmanuelle Charpentier, one of the key figures in the CRISPR landscape.
The University of California will soon be granted a patent related to the gene-editing technology CRISPR, according to a notice of allowance by the US Patent and Trademark Office.